What does this video actually claim?
The TikTok from @np2go demonstrates the basic injection technique for Zepbound (tirzepatide) pens. The creator shows the standard steps: removing the cap, dialing the dose, selecting an injection site, and administering the medication subcutaneously.
The video focuses on the mechanical aspects of using the pre-filled pen device. It's positioned as an educational tutorial for people who've been prescribed this GLP-1 receptor agonist for weight management.
While the demonstration appears technically sound, any injection tutorial should include safety considerations that aren't fully covered in a short social media format.
Does the injection technique look correct?
The basic pen injection method shown matches FDA-approved administration guidelines for Zepbound. The creator demonstrates subcutaneous injection into what appears to be the thigh area, which is one of the three recommended injection sites.
Zepbound's prescribing information specifies injection into the abdomen, thigh, or upper arm, rotating sites with each dose. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) used this same subcutaneous administration method when participants achieved up to 20.9% body weight reduction with 15mg tirzepatide.
However, the video format limits the ability to show proper needle disposal, site rotation strategies, or what to do if you miss a dose. These aren't minor details when you're injecting medication weekly for months.
What safety information is missing?
Short-form social media can't cover everything, but several safety points deserve mention that this video skips. The FDA requires specific warnings about thyroid tumors, pancreatitis risk, and diabetic retinopathy complications with tirzepatide use.
The video doesn't address dose escalation protocols. Zepbound starts at 2.5mg weekly, increasing to 5mg, 7.5mg, 10mg, and potentially 15mg based on tolerance and response. Getting this wrong can mean unnecessary side effects.
Site rotation matters more than the video suggests. Injecting repeatedly in the same area can cause lipodystrophy or reduced absorption. The prescribing information specifically recommends rotating within and between the three approved injection areas.
What should you actually know about Zepbound?
Tirzepatide targets both GLP-1 and GIP receptors, making it mechanistically different from semaglutide-based medications like Wegovy. The SURMOUNT-1 trial showed 15mg tirzepatide led to 20.9% average body weight loss over 72 weeks in adults without diabetes.
The medication costs around $1,000 monthly without insurance coverage. Most insurance plans require prior authorization and documented lifestyle modification attempts before approval.
Common side effects hit hard during dose escalations. Nausea affected 85% of participants at the highest dose in clinical trials, with 16% discontinuing due to gastrointestinal issues. Starting slowly and following the escalation schedule helps, but it's not foolproof.
This isn't a medication you start and stop casually. The SURMOUNT-4 trial (Aronne et al., Nature Medicine, 2023) showed that people regained about half their lost weight within a year of stopping tirzepatide.